Icahn names boardroom nominees for Amylin proxy battle
This article was originally published in Scrip
Executive Summary
The activist investor Carl Icahn has named his five boardroom candidates for Amylin Pharmaceuticals, instigating a three-pronged offensive for control of the company. Mr Icahn joins Eastbourne Capital, which filed its five board candidates for the 12-person board last week.